IPO News | An Xuyuan Technology Announces Hong Kong Stock Exchange Combines Integrated Circuits, Biotechnology and Artificial Intelligence Technology to Create an Advanced Basic Platform for Life Science Research and Clinical Applications

The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on April 30, Axbio International Limited (abbreviation: An Xuyuan Technology) submitted a statement to the Hong Kong Stock Exchange, with CICC and SPDB International as co-sponsors.

According to the prospectus, An Xuyuan Technology was founded in 2016 and is a global leader in integrated circuit biotechnology. It is committed to developing next-generation electrochemical testing platforms to innovate the life science tools and diagnostic industry. The company combines integrated circuits, biotechnology and artificial intelligence technology to create an advanced basic platform for life science research and clinical applications.

The company has advanced technical capabilities and focuses on developing basic life science technology platforms. Its core expertise covers four key areas: integrated circuit chips, synthetic biology and chemical engineering, electrochemistry and microfluidic control, and artificial intelligence. Among them, artificial intelligence is the core of the company's innovation strategy, driving progress in various fields of the platform, including enzyme screening and engineering, product design and optimization, and data and bioinformation analysis. In addition to the overall product pipeline, the company also integrates core technology platforms to provide downstream partners and customers with high-quality chemical synthesis and synthetic biology services, as well as artificial intelligence-driven enzyme screening and engineering services.

Based on the above core technology platforms, the company's pioneering solution consists of a series of products, including a microarray chip platform for multi-target molecular detection, and a next-generation electrochemical long-reading long-reading sequencing platform (EL-NGS) and biochips for multi-omics analysis. As of the last practical date, the company's product pipeline includes a microarray chip analyzer, two EL-NGS gene sequencers, and various supporting test kits.

The company's core product, Axilona EL-100, is one of the few molecular diagnostic products in China that can perform electrochemical, multi-target, fast, low-cost and integrated biomolecular tests. Specifically, Axilona EL-100 is a molecular diagnostic product based on electrochemical biochip technology. This product has many advanced capabilities, such as multiple target detection, high sensitivity, fast detection cycle, and very flexible and easy to use, filling the market gap between PCR instruments and gene sequencers. These characteristics make it very suitable for scientific research and clinical applications, and stand out from molecular diagnostic products. At the same time, the company also plans to further expand the clinical application scope of Axilona EL-100 to seize the huge market opportunities for protein testing by increasing protein detection functions. In June 2024, Axilona EL-100 was included in the Special Examination Procedure for Class II Innovative Medical Devices by the Jiangsu Drug Administration (commonly known as the “Green Channel”). In March 2025, Axilona EL-100 completed clinical trials, and obtained a Class II medical device registration certificate from the Jiangsu Drug Administration in April 2025.

Furthermore, its groundbreaking semiconductor Bio-CMOS chip technology has revolutionized genetic sequencing and molecular diagnosis. The chip is the world's first 300 mm, 65 nm process chip using advanced CMOS principles, and has reached the highest density level in the world with more than 1 million parallel nanopore detection units per chip. Based on this technology, the main product AxiLona AXP-100 genetic sequencer developed by the company is the world's first EL-NGS platform, which achieves the best balance of four key indicators: accuracy, reading length, cost and speed. AxiLona AXP-100 can also meet clinical applications such as cancer and infectious disease diagnosis, as well as scientific research needs such as structural variation research and single-gene disease detection. At the same time, the company also plans to develop Axilona AXP-1000, which features a high-throughput sequencing chip with 10 million nanopore channels, and its throughput is about ten times that of Axilona AXP-100.

According to reports, the company is also launching test kit products such as biochips, reagents, and other necessary consumables, as well as major extension services based on core technology: customized synthesis of chemical products, synthesis of small biological molecules, optimization and improvement of biological activity, high-throughput protein screening and enzyme engineering based on artificial intelligence, and is also actively promoting other products and services such as multi-omic protein testing service solutions.

As a life science company founded in the US and developed in China, the company has been actively promoting a global strategy. Over the years, four R&D centers have been established in response to the strategy, located in Silicon Valley, Shenzhen, Tianjin and Wuxi. Each center is equipped with cutting-edge experimental facilities to support innovative research and development. The company's core R&D personnel have been granted nearly 100 patents worldwide, and several more are pending.

Notably, the company's management and R&D team members all have excellent academic backgrounds and have received professional education at world-renowned institutions such as Stanford University, Yale University, Purdue University, Tsinghua University, and Peking University. The biochemistry and product integration team consists of a number of senior experts who have led the development of genetic sequencing or molecular diagnostic products at well-known institutions such as Life Technologies (acquired by Thermo Fisher), the US Centers for Disease Control and Prevention (CDC), Shenzhen Bay Laboratory Translational Innovation Center, BGI, and many nanopore sequencing companies. The hardware and electronics team consists of experienced technical experts, including integrated circuit design experts, microelectromechanical systems and nanotechnology experts, and software engineers focusing on the development of medical devices and artificial intelligence medical imaging systems. The company's mature and stable R&D team consists of 81 members with backgrounds and industry knowledge in various fields such as semiconductors, biotechnology and artificial intelligence. About 60% of them have doctorate or master's degrees.